Iridius | $8,600,000 | (Apr 28, 2026)
Audion | $15,000,000 | (Apr 28, 2026)
Decade Energy | $25,763,540 | (Apr 28, 2026)
Certified by Founder
Lodge
Illimis Therapeutics
start up
Korea, Republic Of
- Seoul
- 15/07/2025
- Series B
- $42,000,000
Illimis Therapeutics is a platform-based Korean biotech company developing a chimeric fusion protein platform for neurodegenerative diseases such as Alzheimer’s. Our platform is differentiated by its ability to address the concerns of antibody-induced neuroinflammation and subsequent ARIA (Amyloid-Related Imaging Abnormalities) often observed from existing antibody drugs that utilize FcR-mediated phagocytosis of microglia, by utilizing TAM receptor, a novel phagocytic receptor expressed on the surface of glial cells.
- Industry Biotechnology Research
- Website www.illimistx.com
- LinkedIn https://www.linkedin.com/company/illimis-therapeutics/
TriFetch | $1,900,000 | (Apr 28, 2026)
Fathom Therapeutics | $47,000,000 | (Apr 28, 2026)
SquareMind | $18,000,000 | (Apr 28, 2026)
Linexa | $2,342,840 | (Apr 28, 2026)
HrFlow.ai | $7,000,000 | (Apr 28, 2026)
Cnuic Technologies | $3,000,000 | (Apr 28, 2026)
Zócalo Health | $15,000,000 | (Apr 24, 2026)
VREY | $3,859,432 | (Apr 24, 2026)
QMatter | $1,200,000 | (Apr 24, 2026)